October 28, 2022
1 min watch
Save
VIDEO: NovaSight CEO discusses CureSight vs. patching for amblyopia treatment
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Ran Yam, of NovaSight, discusses positive topline study data for the CureSight amblyopia therapy device.
According to Yam, the device was noninferior to patching, with 80% of children in the CureSight treatment group showing a two-line improvement in visual acuity, which was better than the results in the patching treatment group.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Yam reports being the CEO and co-founder of NovaSight.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.